2020 Asthma Guideline Update From the National Asthma Education and Prevention Program | Adolescent Medicine | JN Learning | AMA Ed Hub [Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.204.227.34. Please contact the publisher to request reinstatement.
[Skip to Content Landing]

Managing Asthma in Adolescents and Adults2020 Asthma Guideline Update From the National Asthma Education and Prevention Program

Educational Objective
To review the clinical management of adolescents and adults with asthma.
1 Credit CME
Abstract

Importance  Asthma is a major public health problem worldwide and is associated with excess morbidity, mortality, and economic costs associated with lost productivity. The National Asthma Education and Prevention Program has released the 2020 Asthma Guideline Update with updated evidence-based recommendations for treatment of patients with asthma.

Objective  To report updated recommendations for 6 topics for clinical management of adolescents and adults with asthma: (1) intermittent inhaled corticosteroids (ICSs); (2) add-on long-acting muscarinic antagonists; (3) fractional exhaled nitric oxide; (4) indoor allergen mitigation; (5) immunotherapy; and (6) bronchial thermoplasty.

Evidence Review  The National Heart, Lung, and Blood Advisory Council chose 6 topics to update the 2007 asthma guidelines based on results from a 2014 needs assessment. The Agency for Healthcare Research and Quality conducted systematic reviews of these 6 topics based on literature searches up to March-April 2017. Reviews were updated through October 2018 and used by an expert panel (n = 19) that included asthma content experts, primary care clinicians, dissemination and implementation experts, and health policy experts to develop 19 new recommendations using the GRADE method. The 17 recommendations for individuals aged 12 years or older are reported in this Special Communication.

Findings  From 20 572 identified references, 475 were included in the 6 systematic reviews to form the evidence basis for these recommendations. Compared with the 2007 guideline, there was no recommended change in step 1 (intermittent asthma) therapy (as-needed short-acting β2-agonists [SABAs] for rescue therapy). In step 2 (mild persistent asthma), either daily low-dose ICS plus as-needed SABA therapy or as-needed concomitant ICS and SABA therapy are recommended. Formoterol in combination with an ICS in a single inhaler (single maintenance and reliever therapy) is recommended as the preferred therapy for moderate persistent asthma in step 3 (low-dose ICS-formoterol therapy) and step 4 (medium-dose ICS-formoterol therapy) for both daily and as-needed therapy. A short-term increase in the ICS dose alone for worsening of asthma symptoms is not recommended. Add-on long-acting muscarinic antagonists are recommended in individuals whose asthma is not controlled by ICS-formoterol therapy for step 5 (moderate-severe persistent asthma). Fractional exhaled nitric oxide testing is recommended to assist in diagnosis and monitoring of symptoms, but not alone to diagnose or monitor asthma. Allergen mitigation is recommended only in individuals with exposure and relevant sensitivity or symptoms. When used, allergen mitigation should be allergen specific and include multiple allergen-specific mitigation strategies. Subcutaneous immunotherapy is recommended as an adjunct to standard pharmacotherapy for individuals with symptoms and sensitization to specific allergens. Sublingual immunotherapy is not recommended specifically for asthma. Bronchial thermoplasty is not recommended as part of standard care; if used, it should be part of an ongoing research effort.

Conclusions and Relevance  Asthma is a common disease with substantial human and economic costs globally. Although there is no cure or established means of prevention, effective treatment is available. Use of the recommendations in the 2020 Asthma Guideline Update should improve the health of individuals with asthma.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Corresponding Author: Michelle M. Cloutier, MD, Departments of Pediatrics and Medicine, UCONN Health, 263 Farmington Ave, Farmington, CT 06030 (cloutier@uchc.edu).

Accepted for Publication: October 26, 2020.

Published Online: December 3, 2020. doi:10.1001/jama.2020.21974

Author Contributions: Dr Cloutier had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Cloutier, Dixon, Krishnan, Lemanske, Pace.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Cloutier, Dixon, Krishnan, Lemanske, Pace.

Critical revision of the manuscript for important intellectual content: All authors.

Administrative, technical, or material support: Cloutier, Krishnan, Lemanske.

Supervision: Cloutier, Lemanske.

Conflict of Interest Disclosures: Dr Cloutier reported having a family member employed by Regeneron. Dr Dixon reported receiving a study medication from MitoQ and receiving assistance from a Boehringer Ingelheim medical writer for an article published in 2019 (not related to the update topics). Dr Krishnan reported receiving research funding from the National Heart, Lung, and Blood Institute (NHLBI), Patient-Centered Outcomes Research Institute, Regeneron, Sergey Brin Family Foundation, and Inogen/ResMed for studies not related to the update topics and receiving consulting fees from the Critical Path Institute for work related to developing asthma symptom questionnaires and from Sanofi for serving on an independent data monitoring. Dr Lemanske reported receiving grants from the NHLBI, the National Institutes of Health, Childhood Origins of Asthma (COAST), and AsthmaNet; receiving a National Institutes of Health Clinical and Translational Science Award; and receiving personal fees from Louisiana State University, Elsevier, UpToDate, the Japanese Society of Allergy, the Asia Pacific Association of Allergy, Asthma, and Clinical Immunology and the Asia Pacific Association of Pediatric Allergy, Respirology, and Immunology, Scientific Consultant, the Food Allergy Research and Education Network, and Sciolta Inc. Dr Pace reported serving on an advisory group (1-time meeting) for Mylan concerning revefenacin; being a coinvestigator on grants from the NHLBI, the National Institute of Mental Health, the National Institute on Aging, the National Center for Advancing Translational Sciences, the Centers for Disease Control and Prevention, Tabula Rosa Health Care, and Boehringer Ingelheim for projects not related to the review topics; and receiving grants from the Patient-Centered Outcomes Institute related to asthma therapy but not specifically related to the review topics; he or his wife hold stock in Johnson & Johnson, Eli Lily, Novo Nordisk, Pfizer, Amgen, Gilead, and Novartis. Dr Schatz has received research grants to his institution from Merck, ALK, and Teva; honoraria from UpToDate; and a stipend from the American Academy of Allergy, Asthma, and Immunology for his position as editor in chief of the Journal of Allergy and Clinical Immunology: In Practice.

Funding/Support: The 2020 Asthma Guideline Update report was funded by the NHLBI of the National Institutes of Health.

Role of the Funder/Sponsor: The NHLBI determined the need to update recommendations, contracted with the Agency for Healthcare Research and Quality to select the organizations responsible for conducting the systematic reviews based on the key questions that were developed by the National Heart, Lung and Blood Advisory Council, selected the expert panel members, and provided administrative support and oversight. The expert panel designed and conducted the approach to the review of the evidence; collection, management, analysis, and interpretation of the data; and preparation, review, and approval of the guideline. The updated guidelines were accepted by the National Asthma Education and Prevention Program Coordinating Committee and cleared by the National Institutes of Health.

Additional Contributions: We are grateful to our colleagues on the expert panel; to James P. Kiley, PhD, director, Division of Lung Diseases, NHLBI, and George A. Mensah, MD, director, Center for Translation Research and Implementation Science, NHLBI, for support and encouragement; to Susan Shero, RN, BSN, MS, and Michelle Freemer, MD, MPH, both from the NHLBI, for technical, administrative and editorial support; to Shahnaz Sultan, MD, MHSC, AGAF, University of Minnesota, for expert guidance on using GRADE; to Lenora Johnson, DrPH, MPH, director, Office of Science Policy, Engagement, Education, and Communications, NHLBI, for work on the patient/caregiver focus groups; and to Westat, which provided technical and administrative support. We are also grateful for the comments from the National Asthma Education and Prevention Program Coordinating Committee members, professional societies, the public, nonprofit organizations, and industry. No compensation outside of regular salary was received by any named contributor.

References
1.
Global Asthma Network. Global Asthma Report 2018. Accessed October 14, 2020. http://www.globalasthmanetwork.org
2.
National Asthma Education and Prevention Program Third Expert Panel on the Diagnosis and Management of Asthma. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. National Heart, Lung, and Blood Institute; August 2007. Accessed October 14, 2020. https://www.ncbi.nlm.nih.gov/books/NBK7232/
3.
Expert Panel Working Group of the National Heart, Lung, and Blood Institute.  Focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group.   J Allergy Clin Immunol. 2020;146:1217-1270.Google ScholarCrossref
4.
National Heart, Lung, and Blood Advisory Council Asthma Expert Working Group.  Draft Needs Assessment Report for Potential Update of the Expert Panel Report 3 (2007): Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health/National Heart, Lung, and Blood Institute; 2014.
5.
Wang  Z , Pianosi  P , Keogh  K ,  et al. The Clinical Utility of Fractional Exhaled Nitric Oxide (FeNO) in Asthma Management. Comparative Effectiveness Review No. 197. Rockville, MD: Agency for Healthcare Research and Quality; December 2017. Accessed October 11, 2020. https://effectivehealthcare.ahrq.gov/products/asthma-nitric-oxide/research/
6.
Leas  BF , D’Anci  KE , Apter  AJ , Bryant-Stephens  T , Schoelles  K , Umscheid  C . Effectiveness of Indoor Allergen Reduction in Management of Asthma. Comparative Effectiveness Review No. 201. Rockville, MD: Agency for Healthcare Research and Quality; February 2018. Accessed October 11, 2020. https://effectivehealthcare.ahrq.gov/products/asthma-nonpharmacologic-treatment/final-report-indoor-allergen-reduction
7.
Sobieraj  DM , Baker  WL , Weeda  ER ,  et al. Intermittent Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists for Asthma. Comparative Effectiveness Review No. 194. Rockville, MD: Agency for Healthcare Research and Quality; March 2018. Accessed October 11, 2020. https://effectivehealthcare.ahrq.gov/products/asthma-pharmacologic-treatment/research-2017
8.
Lin  SY , Azar  A , Suarez-Cuervo  C ,  et al. The Role of Immunotherapy in the Treatment of Asthma. Comparative Effectiveness Review No. 196. Rockville, MD: Agency for Healthcare Research and Quality; March 2018:22-23. Accessed October 11, 2020. https://effectivehealthcare.ahrq.gov/products/asthma-immunotherapy/research/
9.
D’Anci  KE , Lynch  MP , Leas  BF ,  et al. Effectiveness and Safety of Bronchial Thermoplasty in Management of Asthma. Comparative Effectiveness Review No. 202. Rockville, MD: Agency for Healthcare Research and Quality; December 2017. Accessed October 11, 2020. https://effectivehealthcare.ahrq.gov/products/asthma-nonpharmacologic-treatment/thermoplasty-systematic-review
10.
Graham  R , Mancher  M , Miller Wolman  D , Greenfield  S , Steinberg  E , eds; Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice Guidelines.  Clinical Practice Guidelines We Can Trust. National Academies Press; 2011. Accessed October 11, 2020. https://www.ncbi.nlm.nih.gov/books/NBK209539/
11.
Qaseem  A , Wilt  TJ ; Clinical Guidelines Committee of the American College of Physicians.  Disclosure of interests and management of conflicts of interest in clinical guidelines and guidance statements.   Ann Intern Med. 2019;171(5):354-361. doi:10.7326/M18-3279PubMedGoogle ScholarCrossref
12.
Guyatt  G , Oxman  AD , Akl  EA ,  et al.  GRADE guidelines, 1: introduction-GRADE evidence profiles and summary of findings tables.   J Clin Epidemiol. 2011;64(4):383-394. doi:10.1016/j.jclinepi.2010.04.026PubMedGoogle ScholarCrossref
13.
Brożek  J , Nowak  A , Kunstman  P , Schünemann  H . GRADEpro Guideline Development Tool (G2DT). Accessed October 11, 2020. https://gradepro.org/
14.
Busse  WW , Morgan  WJ , Taggart  V , Togias  A .  Asthma Outcomes Workshop: overview.   J Allergy Clin Immunol. 2012;129(3)(suppl):S1-S8. doi:10.1016/j.jaci.2011.12.985PubMedGoogle ScholarCrossref
15.
Fuhlbrigge  A , Peden  D , Apter  AJ ,  et al.  Asthma outcomes: exacerbations.   J Allergy Clin Immunol. 2012;129(3)(suppl):S34-S48. doi:10.1016/j.jaci.2011.12.983PubMedGoogle ScholarCrossref
16.
Guyatt  GH , Oxman  AD , Kunz  R ,  et al; GRADE Working Group.  GRADE guidelines, 8: rating the quality of evidence—indirectness.   J Clin Epidemiol. 2011;64(12):1303-1310. doi:10.1016/j.jclinepi.2011.04.014PubMedGoogle ScholarCrossref
17.
Calhoun  WJ , Ameredes  BT , King  TS ,  et al; Asthma Clinical Research Network of the National Heart, Lung, and Blood Institute.  Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial.   JAMA. 2012;308(10):987-997. doi:10.1001/2012.jama.10893PubMedGoogle ScholarCrossref
18.
Camargos  P , Affonso  A , Calazans  G ,  et al.  On-demand intermittent beclomethasone is effective for mild asthma in Brazil.   Clin Transl Allergy. 2018;8:7. doi:10.1186/s13601-018-0192-0PubMedGoogle ScholarCrossref
19.
Papi  A , Canonica  GW , Maestrelli  P ,  et al; BEST Study Group.  Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma.   N Engl J Med. 2007;356(20):2040-2052. doi:10.1056/NEJMoa063861PubMedGoogle ScholarCrossref
20.
Harrison  TW , Oborne  J , Newton  S , Tattersfield  AE .  Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial.   Lancet. 2004;363(9405):271-275. doi:10.1016/S0140-6736(03)15384-6PubMedGoogle ScholarCrossref
21.
Lahdensuo  A , Haahtela  T , Herrala  J ,  et al.  Randomised comparison of guided self management and traditional treatment of asthma over one year.   BMJ. 1996;312(7033):748-752. doi:10.1136/bmj.312.7033.748PubMedGoogle ScholarCrossref
22.
Oborne  J , Mortimer  K , Hubbard  RB , Tattersfield  AE , Harrison  TW .  Quadrupling the dose of inhaled corticosteroid to prevent asthma exacerbations: a randomized, double-blind, placebo-controlled, parallel-group clinical trial.   Am J Respir Crit Care Med. 2009;180(7):598-602. doi:10.1164/rccm.200904-0616OCPubMedGoogle ScholarCrossref
23.
McKeever  T , Mortimer  K , Wilson  A ,  et al.  Quadrupling inhaled glucocorticoid dose to abort asthma exacerbations.   N Engl J Med. 2018;378(10):902-910. doi:10.1056/NEJMoa1714257PubMedGoogle ScholarCrossref
24.
Bisgaard  H , Le Roux  P , Bjåmer  D , Dymek  A , Vermeulen  JH , Hultquist  C .  Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma.   Chest. 2006;130(6):1733-1743. doi:10.1378/chest.130.6.1733PubMedGoogle ScholarCrossref
25.
Atienza  T , Aquino  T , Fernández  M ,  et al.  Budesonide/formoterol maintenance and reliever therapy via Turbuhaler versus fixed-dose budesonide/formoterol plus terbutaline in patients with asthma: phase III study results.   Respirology. 2013;18(2):354-363. doi:10.1111/resp.12009PubMedGoogle ScholarCrossref
26.
Papi  A , Corradi  M , Pigeon-Francisco  C ,  et al.  Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial.   Lancet Respir Med. 2013;1(1):23-31. doi:10.1016/S2213-2600(13)70012-2PubMedGoogle ScholarCrossref
27.
Patel  M , Pilcher  J , Pritchard  A ,  et al; SMART Study Group.  Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial.   Lancet Respir Med. 2013;1(1):32-42. doi:10.1016/S2213-2600(13)70007-9PubMedGoogle ScholarCrossref
28.
Rabe  KF , Atienza  T , Magyar  P , Larsson  P , Jorup  C , Lalloo  UG .  Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study.   Lancet. 2006;368(9537):744-753. doi:10.1016/S0140-6736(06)69284-2PubMedGoogle ScholarCrossref
29.
Vogelmeier  C , D’Urzo  A , Pauwels  R ,  et al.  Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?   Eur Respir J. 2005;26(5):819-828. doi:10.1183/09031936.05.00028305PubMedGoogle ScholarCrossref
30.
Bousquet  J , Boulet  LP , Peters  MJ ,  et al.  Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone.   Respir Med. 2007;101(12):2437-2446. doi:10.1016/j.rmed.2007.07.014PubMedGoogle ScholarCrossref
31.
Kuna  P , Peters  MJ , Manjra  AI ,  et al.  Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations.   Int J Clin Pract. 2007;61(5):725-736. doi:10.1111/j.1742-1241.2007.01338.xPubMedGoogle ScholarCrossref
32.
Bateman  ED , Kornmann  O , Schmidt  P , Pivovarova  A , Engel  M , Fabbri  LM .  Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma.   J Allergy Clin Immunol. 2011;128(2):315-322. doi:10.1016/j.jaci.2011.06.004PubMedGoogle ScholarCrossref
33.
Kerstjens  HA , Casale  TB , Bleecker  ER ,  et al.  Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials.   Lancet Respir Med. 2015;3(5):367-376. doi:10.1016/S2213-2600(15)00031-4PubMedGoogle ScholarCrossref
34.
Lee  LA , Yang  S , Kerwin  E , Trivedi  R , Edwards  LD , Pascoe  S .  The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging study.   Respir Med. 2015;109(1):54-62. doi:10.1016/j.rmed.2014.09.012PubMedGoogle ScholarCrossref
35.
Peters  SP , Kunselman  SJ , Icitovic  N ,  et al; National Heart, Lung, and Blood Institute Asthma Clinical Research Network.  Tiotropium bromide step-up therapy for adults with uncontrolled asthma.   N Engl J Med. 2010;363(18):1715-1726. doi:10.1056/NEJMoa1008770PubMedGoogle ScholarCrossref
36.
Rajanandh  MG , Nageswari  AD , Ilango  K .  Pulmonary function assessment in mild to moderate persistent asthma patients receiving montelukast, doxofylline, and tiotropium with budesonide: a randomized controlled study.   Clin Ther. 2014;36(4):526-533. doi:10.1016/j.clinthera.2014.02.006PubMedGoogle ScholarCrossref
37.
Wechsler  ME , Yawn  BP , Fuhlbrigge  AL ,  et al; BELT Investigators.  Anticholinergic vs long-acting β-agonist in combination with inhaled corticosteroids in Black adults with asthma: the BELT randomized clinical trial.   JAMA. 2015;314(16):1720-1730. doi:10.1001/jama.2015.13277PubMedGoogle ScholarCrossref
38.
Hamelmann  E , Bateman  ED , Vogelberg  C ,  et al.  Tiotropium add-on therapy in adolescents with moderate asthma: a 1-year randomized controlled trial.   J Allergy Clin Immunol. 2016;138(2):441-450.e8. doi:10.1016/j.jaci.2016.01.011PubMedGoogle ScholarCrossref
39.
Paggiaro  P , Halpin  DM , Buhl  R ,  et al.  The effect of tiotropium in symptomatic asthma despite low- to medium-dose inhaled corticosteroids: a randomized controlled trial.   J Allergy Clin Immunol Pract. 2016;4(1):104-13.e2. doi:10.1016/j.jaip.2015.08.017PubMedGoogle ScholarCrossref
40.
Ohta  K , Ichinose  M , Tohda  Y ,  et al.  Long-term once-daily tiotropium Respimat is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo-controlled study.   PLoS One. 2015;10(4):e0124109. doi:10.1371/journal.pone.0124109PubMedGoogle Scholar
41.
Kerstjens  HA , Engel  M , Dahl  R ,  et al.  Tiotropium in asthma poorly controlled with standard combination therapy.   N Engl J Med. 2012;367(13):1198-1207. doi:10.1056/NEJMoa1208606PubMedGoogle ScholarCrossref
42.
Fahy  JV .  Type 2 inflammation in asthma—present in most, absent in many.   Nat Rev Immunol. 2015;15(1):57-65. doi:10.1038/nri3786PubMedGoogle ScholarCrossref
43.
Dweik  RA , Boggs  PB , Erzurum  SC ,  et al; American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FeNO) for Clinical Applications.  An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FeNO) for clinical applications.   Am J Respir Crit Care Med. 2011;184(5):602-615. doi:10.1164/rccm.9120-11STPubMedGoogle ScholarCrossref
44.
Shaw  DE , Berry  MA , Thomas  M ,  et al.  The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial.   Am J Respir Crit Care Med. 2007;176(3):231-237. doi:10.1164/rccm.200610-1427OCPubMedGoogle ScholarCrossref
45.
Syk  J , Malinovschi  A , Johansson  G ,  et al.  Anti-inflammatory treatment of atopic asthma guided by exhaled nitric oxide: a randomized, controlled trial.   J Allergy Clin Immunol Pract. 2013;1(6):639-648.PubMedGoogle ScholarCrossref
46.
Szefler  SJ , Mitchell  H , Sorkness  CA ,  et al.  Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial.   Lancet. 2008;372(9643):1065-1072. doi:10.1016/S0140-6736(08)61448-8PubMedGoogle ScholarCrossref
47.
Honkoop  PJ , Loijmans  RJ , Termeer  EH ,  et al; Asthma Control Cost-Utility Randomized Trial Evaluation Study Group.  Symptom- and fraction of exhaled nitric oxide-driven strategies for asthma control: a cluster-randomized trial in primary care.   J Allergy Clin Immunol. 2015;135(3):682-8.e11. doi:10.1016/j.jaci.2014.07.016PubMedGoogle ScholarCrossref
48.
Pike  K , Selby  A , Price  S ,  et al.  Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid dose in paediatric asthma: a randomised controlled trial.   Clin Respir J. 2013;7(2):204-213. doi:10.1111/j.1752-699X.2012.00306.xPubMedGoogle ScholarCrossref
49.
Carter  MC , Perzanowski  MS , Raymond  A , Platts-Mills  TA .  Home intervention in the treatment of asthma among inner-city children.   J Allergy Clin Immunol. 2001;108(5):732-737. doi:10.1067/mai.2001.119155PubMedGoogle ScholarCrossref
50.
Krieger  JW , Takaro  TK , Song  L , Weaver  M .  The Seattle-King County Healthy Homes Project: a randomized, controlled trial of a community health worker intervention to decrease exposure to indoor asthma triggers.   Am J Public Health. 2005;95(4):652-659. doi:10.2105/AJPH.2004.042994PubMedGoogle ScholarCrossref
51.
Morgan  WJ , Crain  EF , Gruchalla  RS ,  et al; Inner-City Asthma Study Group.  Results of a home-based environmental intervention among urban children with asthma.   N Engl J Med. 2004;351(11):1068-1080. doi:10.1056/NEJMoa032097PubMedGoogle ScholarCrossref
52.
Parker  EA , Israel  BA , Robins  TG ,  et al.  Evaluation of Community Action Against Asthma: a community health worker intervention to improve children’s asthma-related health by reducing household environmental triggers for asthma.   Health Educ Behav. 2008;35(3):376-395. doi:10.1177/1090198106290622PubMedGoogle Scholar
53.
Bryant-Stephens  T , Kurian  C , Guo  R , Zhao  H .  Impact of a household environmental intervention delivered by lay health workers on asthma symptom control in urban, disadvantaged children with asthma.   Am J Public Health. 2009;99(suppl 3):S657-S665. doi:10.2105/AJPH.2009.165423PubMedGoogle Scholar
54.
Bryant-Stephens  T , Li  Y .  Outcomes of a home-based environmental remediation for urban children with asthma.   J Natl Med Assoc. 2008;100(3):306-316. doi:10.1016/S0027-9684(15)31243-8PubMedGoogle Scholar
55.
Eggleston  PA , Butz  A , Rand  C ,  et al.  Home environmental intervention in inner-city asthma: a randomized controlled clinical trial.   Ann Allergy Asthma Immunol. 2005;95(6):518-524. doi:10.1016/S1081-1206(10)61012-5PubMedGoogle Scholar
56.
Evans  R  III , Gergen  PJ , Mitchell  H ,  et al.  A randomized clinical trial to reduce asthma morbidity among inner-city children: results of the National Cooperative Inner-City Asthma Study.   J Pediatr. 1999;135(3):332-338. doi:10.1016/S0022-3476(99)70130-7PubMedGoogle Scholar
57.
Matsui  EC , Perzanowski  M , Peng  RD ,  et al.  Effect of an integrated pest management intervention on asthma symptoms among mouse-sensitized children and adolescents with asthma: a randomized clinical trial.   JAMA. 2017;317(10):1027-1036. doi:10.1001/jama.2016.21048PubMedGoogle Scholar
58.
Pifferi  M , Baldini  G , Marrazzini  G ,  et al.  Benefits of immunotherapy with a standardized Dermatophagoides pteronyssinus extract in asthmatic children: a three-year prospective study.   Allergy. 2002;57(9):785-790. doi:10.1034/j.1398-9995.2002.23498.xPubMedGoogle Scholar
59.
Ameal  A , Vega-Chicote  JM , Fernández  S ,  et al.  Double-blind and placebo-controlled study to assess efficacy and safety of a modified allergen extract of Dermatophagoides pteronyssinus in allergic asthma.   Allergy. 2005;60(9):1178-1183. doi:10.1111/j.1398-9995.2005.00862.xPubMedGoogle Scholar
60.
García-Robaina  JC , Sánchez  I , de la Torre  F , Fernández-Caldas  E , Casanovas  M .  Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study.   J Allergy Clin Immunol. 2006;118(5):1026-1032. doi:10.1016/j.jaci.2006.07.043PubMedGoogle Scholar
61.
Kiliç  M , Altintaş  DU , Yilmaz  M , Bingöl-Karakoç  G , Burgut  R , Güneşer-Kendirli  S .  Evaluation of efficacy of immunotherapy in children with asthma monosensitized to Alternaria.   Turk J Pediatr. 2011;53(3):285-294.PubMedGoogle Scholar
62.
Lozano  J , Cruz  MJ , Piquer  M , Giner  MT , Plaza  AM .  Assessing the efficacy of immunotherapy with a glutaraldehyde-modified house dust mite extract in children by monitoring changes in clinical parameters and inflammatory markers in exhaled breath.   Int Arch Allergy Immunol. 2014;165(2):140-147. doi:10.1159/000368832PubMedGoogle Scholar
63.
Olsen  OT , Larsen  KR , Jacobsan  L , Svendsen  UG .  A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults.   Allergy. 1997;52(8):853-859. doi:10.1111/j.1398-9995.1997.tb02157.xPubMedGoogle Scholar
64.
de Blay  F , Kuna  P , Prieto  L ,  et al.  SQ HDM SLIT-tablet (ALK) in treatment of asthma--post hoc results from a randomised trial.   Respir Med. 2014;108(10):1430-1437. doi:10.1016/j.rmed.2014.07.017PubMedGoogle Scholar
65.
Virchow  JC , Backer  V , Kuna  P ,  et al.  Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial.   JAMA. 2016;315(16):1715-1725. doi:10.1001/jama.2016.3964PubMedGoogle Scholar
66.
Devillier  P , Fadel  R , de Beaumont  O .  House dust mite sublingual immunotherapy is safe in patients with mild-to-moderate, persistent asthma: a clinical trial.   Allergy. 2016;71(2):249-257. doi:10.1111/all.12791PubMedGoogle Scholar
67.
Marogna  M , Braidi  C , Bruno  ME ,  et al.  The contribution of sublingual immunotherapy to the achievement of control in birch-related mild persistent asthma: a real-life randomised trial.   Allergol Immunopathol (Madr). 2013;41(4):216-224. doi:10.1016/j.aller.2012.07.004PubMedGoogle Scholar
68.
Gomez  VJ , Flores  SG , Orea  SM , Lopez  TJ , Jimenez  SN .  Safety and efficacy of specific sublingual immunotherapy in patients with asthma and allergy to Dermatophagoides pteronyssinus [in Spanish].   Rev Alerg Mex. 2005;52(6):231-236.PubMedGoogle Scholar
69.
Niu  CK , Chen  WY , Huang  JL , Lue  KH , Wang  JY .  Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multi-center, double-blind, randomized, and placebo-controlled study in Taiwan.   Respir Med. 2006;100(8):1374-1383. doi:10.1016/j.rmed.2005.11.016PubMedGoogle Scholar
70.
Marogna  M , Colombo  F , Spadolini  I ,  et al.  Randomized open comparison of montelukast and sublingual immunotherapy as add-on treatment in moderate persistent asthma due to birch pollen.   J Investig Allergol Clin Immunol. 2010;20(2):146-152.PubMedGoogle Scholar
71.
Marogna  M , Spadolini  I , Massolo  A ,  et al.  Long-term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due to grass pollen.   Ann Allergy Asthma Immunol. 2009;102(1):69-75. doi:10.1016/S1081-1206(10)60111-1PubMedGoogle Scholar
72.
Cox  G , Thomson  NC , Rubin  AS ,  et al; AIR Trial Study Group.  Asthma control during the year after bronchial thermoplasty.   N Engl J Med. 2007;356(13):1327-1337. doi:10.1056/NEJMoa064707PubMedGoogle Scholar
73.
Pavord  ID , Cox  G , Thomson  NC ,  et al; RISA Trial Study Group.  Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma.   Am J Respir Crit Care Med. 2007;176(12):1185-1191. doi:10.1164/rccm.200704-571OCPubMedGoogle Scholar
74.
Thomson  NC , Rubin  AS , Niven  RM ,  et al; AIR Trial Study Group.  Long-term (5 year) safety of bronchial thermoplasty: Asthma Intervention Research (AIR) trial.   BMC Pulm Med. 2011;11:8. doi:10.1186/1471-2466-11-8PubMedGoogle Scholar
75.
Wechsler  ME , Laviolette  M , Rubin  AS ,  et al; Asthma Intervention Research 2 Trial Study Group.  Bronchial thermoplasty: long-term safety and effectiveness in patients with severe persistent asthma.   J Allergy Clin Immunol. 2013;132(6):1295-1302. doi:10.1016/j.jaci.2013.08.009PubMedGoogle Scholar
76.
Juniper  EF , Guyatt  GH , Epstein  RS , Ferrie  PJ , Jaeschke  R , Hiller  TK .  Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.   Thorax. 1992;47(2):76-83. doi:10.1136/thx.47.2.76PubMedGoogle Scholar
77.
Tripple  JW , Ameredes  BT , Calhoun  WJ .  Outpatient management of chronic asthma in 2020.   JAMA. 2020;323(6):561-562. doi:10.1001/jama.2019.19986PubMedGoogle Scholar
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close